Generic Incivek Availability

Incivek is a brand name of telaprevir, approved by the FDA in the following formulation(s):

INCIVEK (telaprevir - tablet;oral)

  • Manufacturer: VERTEX PHARMS
    Approval date: May 23, 2011
    Strength(s): 375MG [RLD]

Has a generic version of Incivek been approved?

No. There is currently no therapeutically equivalent version of Incivek available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Incivek. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Peptidomimetic protease inhibitors
    Patent 7,820,671
    Issued: October 26, 2010
    Inventor(s): Babine; Robert Edward & Chen; Shu Hui & Collado; Ivan & Garcia-Paredes; Cristina & Glass; John Irvin & Guo; Deqi & Jin; Ling & Lamar; Jason Eric & Parker, III; Raymond Samuel & Snyder; Nancy June & Sun; Xicheng David & Tebbe; Mark Joseph & Victor; Frantz & Wang; Q. May & Yip; Yvonne
    Assignee(s): Vertex Pharmaceuticals Incorporated
    The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
    Patent expiration dates:
    • February 25, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Dose forms
    Patent 8,431,615
    Issued: April 30, 2013
    Assignee(s): Vertex Pharmaceuticals Incorporated
    The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
    Patent expiration dates:
    • May 30, 2028
      ✓ 
      Patent use: METHOD OF TREATING CHRONIC HEPATITIS C
  • Peptidomimetic protease inhibitors
    Patent 8,529,882
    Issued: September 10, 2013
    Assignee(s): Vertex Pharmaceuticals Incorporated
    The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.
    Patent expiration dates:
    • August 31, 2021
      ✓ 
      Patent use: METHOD OF TREATING CHRONIC HEPATITIS C

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 23, 2016 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)